<DOC>
	<DOCNO>NCT02082678</DOCNO>
	<brief_summary>The purpose study determine ondansetron , add-on therapy , associate reduce depressive symptom alcohol use outpatient bipolar disorder ( BPD ) . The investigator also use blood sample determine genotype serotonin transporter gene associate response ondansetron .</brief_summary>
	<brief_title>Ondansetron Bipolar Disorder Alcohol Use Disorders</brief_title>
	<detailed_description>A total 70 outpatient alcohol use disorder BPD enrol 12-week , randomize , double-blind , parallel-group , placebo-controlled study ondansetron . Participant receive either ondansetron placebo 12 week . He equal chance receive ondansetron placebo . Randomization stratify base &gt; 4 ≤ 4 drinking day per week start study . Ondansetron placebo give 0.5 milligram twice day first 4 week . At week 4 , 8 10 dose may increase 1.0 , 2.0 4.0 milligram twice day , respectively , significant reduction depression alcohol use observe participant experiencing side effect . Blood drawn routine laboratory analysis include complete blood count ( CBC ) , liver panel , CDT baseline week 4 , 8 12 . Each participant return weekly follow-up visit repeat outcome measure . Pill count conduct , list current medication dos record visit . Participants compensate appointment bus pas , gift card , monetary incentive compliance . Participants evaluate research assistant ( RA ) principal investigator ( PI ) visit . The HAMD Timeline Followback give visit primary outcome measure . Cognitive assessment perform baseline week 12 .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Alcohol Drinking</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<criteria>Outpatient men woman age 1865 year old bipolar I , II , NOS disorder Current depress mood state Current diagnosis alcohol use disorder ( DSM V terminology ) onset ≤ age 25 Alcohol use ( selfreport ) least 15 drink 7 day prior intake Current mood stabilizer therapy ( lithium , anticonvulsant , atypical antipsychotic ) stable dose least 14 day prior randomization Baseline YMRS HAMD score ≥ 35 exclude severe mood symptom Evidence clinically significant alcohol withdrawal symptom define CIWAAr score ≥ 10 Therapy past 14 day naltrexone , acamprosate , disulfiram , topiramate Vulnerable population ( e.g . pregnant , breastfeeding , incarcerate , cognitively impaired ( e.g . dementia , mentally challenge ) ) High risk suicide define &gt; 1 attempt past 12 month require medical attention , attempt past 3 month current suicidal ideation plan intent outpatient care preclude Intensive outpatient treatment ( define ≥ 3 visit week ) substance abuse ( AA , NA meeting , less intensive counseling baseline allow ) Severe lifethreatening medical condition ( e.g. , hepatic cirrhosis ) laboratory physical examination finding consistent serious medical illness ( e.g. , dangerously abnormal electrolyte ) AST ALT &gt; 3 time upper limit normal History severe side effect allergic reaction prior ondansetron therapy ( e.g . vomit ) use medication significant drugdrug interaction ondansetron ( phenytoin , carbamazepine , rifampicin , apomorphine , tramadol )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Bipolar Disorder</keyword>
	<keyword>BPD</keyword>
	<keyword>Alcohol Use Disorder</keyword>
	<keyword>Alcohol Abuse</keyword>
	<keyword>Alcohol Dependence</keyword>
	<keyword>Ondansetron</keyword>
	<keyword>Cognition</keyword>
	<keyword>Mood</keyword>
</DOC>